บันทึกจากแหล่งปฐมภูมิ
The FDA has approved LYTENAVA (bevacizumab-vikg) as the first and only ophthalmic formulation of bevacizumab for wet AMD. This approval grants 12 years of market exclusivity under the BPCIA and establishes a purpose-built, FDA-approved product for intravitreal use. Outlook Therapeutics is now launching commercial operations and expects product availability before year-end.
EX-99.1 2 tm2621316d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation Company Launches Commercial Franchise Positioned to Establish a New Standard as an FDA-Approved Bevacizumab Therapy Across the Approximately $8.5 Billion U.S. Retina Market Anticipated 12 Years of Market Exclusivity Under the Biologics Price Competition and Innovation Act (BPCIA) ISELIN, N.J., July 24, 2026 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biophar maceutica